Inhibitor outperforms rivals in leukemia, lymphoma

Print Friendly, PDF & Email


Researchers in the lab
Photo by Rhoda Baer
Preclinical research suggests the pan-FLT3/pan-BTK inhibitor CG’806 is more effective than other kinase inhibitors in fighting certain hematologic malignancies. In one study, CG’806 proved more potent than comparator drugs in primary samples of acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL). In another study,... [Read Article]
Print Friendly, PDF & Email

Antibody has ‘potent’ effects against AML

Print Friendly, PDF & Email


Micrograph showing AML
Image from Paulo
Henrique Orlandi Mourao
The bispecific antibody APVO436 has demonstrated robust T-cell activation with limited cytokine release in acute myeloid leukemia (AML), according to researchers. APVO436 binds CD123 and CD3 to redirect T-cell cytotoxicity against CD123-expressing tumor cells. Researchers found that APVO436 induced T-cell cytotoxicity in AML cells in... [Read Article]
Print Friendly, PDF & Email

Drug appears to aid chemo in AML

Print Friendly, PDF & Email


Nurse bandaging
chemotherapy patient
Photo by Rhoda Baer
Adding an experimental compound to chemotherapy is a “promising” treatment approach for certain patients with acute myeloid leukemia (AML), according to researchers. They tested the compound, CPI-613, in combination with high-dose cytarabine and mitoxantrone in a phase 1 trial of patients with relapsed or refractory AML.... [Read Article]
Print Friendly, PDF & Email

Drug shows promise for treating AML, MDS

Print Friendly, PDF & Email


Lab mouse
Preclinical results support clinical testing of an experimental agent in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), according to researchers. The agent, ALRN-6924, was shown to combat AML and MDS by restoring activity of the tumor-suppressing protein p53. ALRN-6924 exhibited antileukemic activity in AML cells and mouse models of the disease, as... [Read Article]
Print Friendly, PDF & Email

Gene variants linked to survival after HSCT

Print Friendly, PDF & Email


DNA helix
Image by Spencer Phillips
New research has revealed a link between rare gene variants and survival after hematopoietic stem cell transplant (HSCT). Researchers performed exome sequencing in nearly 2500 HSCT recipients and their matched, unrelated donors. The sequencing revealed several gene variants—in both donors and recipients—that were significantly associated with overall survival... [Read Article]
Print Friendly, PDF & Email

Agent exhibits activity in leukemias, MDS

Print Friendly, PDF & Email


AML cells
The experimental agent prexigebersen (formerly BP1001) was considered well-tolerated and demonstrated early evidence of activity against relapsed/refractory hematologic disorders in a phase 1/1b trial. The drug reduced blasts in the bone marrow and peripheral blood for patients with acute myeloid leukemia (AML), chronic myeloid leukemia (CML), and myelodysplastic syndrome (MDS). When given... [Read Article]
Print Friendly, PDF & Email

Drug receives orphan designation for AML

Print Friendly, PDF & Email


Micrograph showing AML
Image from Paulo
Henrique Orlandi Mourao
The US Food and Drug Administration (FDA) has granted orphan designation to MAX-40279 for the treatment of acute myeloid leukemia (AML). MAX-40279 is a multi-target kinase inhibitor being developed by MaxiNovel Pharmaceuticals, Inc. The drug mainly targets FMS-related tyrosine kinase 3 (FLT3) and fibroblast growth... [Read Article]
Print Friendly, PDF & Email

Manufactured graft deemed safe in blood cancer patients

Print Friendly, PDF & Email


Peripheral blood
stem cell graft
Phase 1 results suggest a programmed cellular therapy is safe for use in patients with hematologic malignancies. The therapy, ProTmune, is being developed as a next-generation allogeneic graft intended to reduce the incidence and severity of acute graft-versus-host disease (GVHD) after hematopoietic stem cell transplant (HSCT). Three of 7... [Read Article]
Print Friendly, PDF & Email